The study: Multi-centre, double-blind, randomised controlled trial (RCT) with intention-to-treat analysis.
Study patients:
Patients older than 16 with septic shock resistant to fluids and vasopressor use of >5 µg/min norepinephrine or equivalent within the last 24 hours, were recruited in their first 24 hours of treatment. Stratification of septic shock was based on pre-randomisation vasopressor levels. Exclusions included acute coronary syndrome or cardiogenic shock, greater than 24 hours elapsing since the patient met entry criteria, prior use of vasopressin, malignancy or proven/suspected acute mesenteric ischaemia.
All patients: received unlabelled 'study-drug' to reach a target mean arterial pressure (MAP) of 65-75 mm Hg. Open-label vasopressors were also used to reach/maintain target MAP during and after study drug titration (The open-label vasopressors were increased only if the target MAP was not reached on maximal study-drug infusion). Standard ICU care of the septic patient was also given. The study drug was continued for as long as required unless predetermined adverse events occurred (cardiac events, evidence of organ or tissue ischaemia, hyponatraemia). 
Low dose vasopressin in septic shock
The addition of low-dose vasopressin to the treatment of septic shock does not reduce mortality compared to the use of norepinephrine alone, but allows a rapid reduction in norepinephrine requirements. 
Level of evidence: 1 + (RCT with a very low risk of bias)

Appraised by: R Docking, K Rooney
The evidence:
Key CER: control event rate EER: experimental event rate RRR: relative risk reduction ARR: absolute risk reduction NNT: number needed to treat suggested future trials looking at vasopressin in 'less severe' septic shock. 6. Did they make recommendations and are these appropriate?
No. 7. Is this study relevant to my clinical practice? Although this is a well-designed RCT, it does not address the issue of catecholamine-refractory septic shock -a setting where vasopressin is more commonly used. Important patient groups such as those with cardiac disease or with acute coronary syndrome were excluded from the trial, and as such we are unable to assess how common adverse events would have been in these groups. 8. What level of evidence does this represent? 1 + 9. What grade of recommendation can I make on this alone? B 10.What grade of recommendation can I make when this study is considered along with other available evidence? B 11.Should I change my practice in light of this study? Possibly not -vasopressin is commonly used in catecholaminerefractory shock, which is not fully addressed by this RCT. 12.Should I audit my practice because of this paper? No.
